Recent Advances in Glycyrrhetinic Acid-Functionalized Biomaterials for Liver Cancer-Targeting Therapy
Open Access
Abstract
Liver cancer is one of the most common causes of cancer mortality worldwide. Chemotherapy and radiotherapy are the conventional therapies generally employed in patients with liver tumors. The major issue associated with the administration of chemotherapeutics is their high toxicity and lack of selectivity, leading to systemic toxicity that can be detrimental to the patient’s quality of life. An important approach to the development of original liver-targeted therapeutic products takes advantage of the employment of biologically active ligands able to bind specific receptors on the cytoplasmatic membranes of liver cells. In this perspective, glycyrrhetinic acid (GA), a pentacyclic triterpenoid present in roots and rhizomes of licorice, has been used as a ligand for targeting the liver due to the expression of GA receptors on the sinusoidal surface of mammalian hepatocytes, so it may be employed to modify drug delivery systems (DDSs) and obtain better liver or hepatocyte drug uptake and efficacy. In the current review, we focus on the most recent and interesting research advances in the development of GA-based hybrid compounds and DDSs developed for potential employment as efficacious therapeutic options for the treatment of hepatic cancer.Keywords
This publication has 108 references indexed in Scilit:
- Concepts and practices used to develop functional PLGA-based nanoparticulate systemsInternational Journal of Nanomedicine, 2013
- 18β‐glycyrrhetinic acid inhibits hepatocellular carcinoma development by reversing hepatic stellate cell‐mediated immunosuppression in miceInternational Journal of Cancer, 2012
- Dysregulated pH: a perfect storm for cancer progressionNature Reviews Cancer, 2011
- Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agentsBioorganic & Medicinal Chemistry Letters, 2010
- Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracilDrug Delivery, 2010
- Active targeting schemes for nanoparticle systems in cancer therapeuticsAdvanced Drug Delivery Reviews, 2008
- Modulation of mitochondrial membrane permeability in pathogenesis, autophagy and control of metabolismJournal of Gastroenterology and Hepatology, 2007
- Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: Clinical implications and therapeutic targeting strategiesJournal of Theoretical Biology, 2006
- Intercellular Communication and Human Hepatocellular CarcinomaAnnals of the New York Academy of Sciences, 2004
- Specific binding of glycyrrhetinic acid to the rat liver membraneBiochimica et Biophysica Acta (BBA) - Biomembranes, 1991